Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA

Spinocerebellar ataxias are progressive neurodegenerative disorders primarily affecting the cerebellum. Although the first disease-causing gene was identified nearly 30 years ago, there is no known cure to date, and only a few options exist for symptomatic treatment, with modest effects. The recentl...

Full description

Bibliographic Details
Main Authors: Chih-Chun Lin, Tetsuo Ashizawa, Sheng-Han Kuo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00902/full
id doaj-1aa94ff079384fb8b70019cd3276162c
record_format Article
spelling doaj-1aa94ff079384fb8b70019cd3276162c2020-11-25T03:51:32ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-08-011110.3389/fneur.2020.00902564946Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCAChih-Chun Lin0Chih-Chun Lin1Tetsuo Ashizawa2Sheng-Han Kuo3Sheng-Han Kuo4Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, United StatesInitiative for Columbia Ataxia and Tremor, Columbia University, New York, NY, United StatesDepartment of Neurology, Houston Methodist Research Institute, Houston, TX, United StatesDepartment of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, United StatesInitiative for Columbia Ataxia and Tremor, Columbia University, New York, NY, United StatesSpinocerebellar ataxias are progressive neurodegenerative disorders primarily affecting the cerebellum. Although the first disease-causing gene was identified nearly 30 years ago, there is no known cure to date, and only a few options exist for symptomatic treatment, with modest effects. The recently developed tools in molecular biology, such as CRISPR/Cas9 and antisense oligonucleotides, can directly act on the disease mechanisms at the genomic or RNA level in disease models. In a nutshell, we are finally just one step away from clinical trials with therapies targeting the underlying genetic cause. However, we still face the challenges for rare neurodegenerative diseases: difficulty in obtaining a large cohort size for sufficient statistical power and the need for biomarkers and clinical outcome assessments (COA) with adequate sensitivity to reflect progression or treatment responses. To overcome these obstacles, ataxia experts form research networks for clinical trial readiness. In this review, we retrace our steps of the collaborative efforts among ataxia researchers in the United States over the years to study and treat these relentless disorders and the future directions of such research networks.https://www.frontiersin.org/article/10.3389/fneur.2020.00902/fullataxiacerebellumnetworkconsortiumspinocerebellar ataxia
collection DOAJ
language English
format Article
sources DOAJ
author Chih-Chun Lin
Chih-Chun Lin
Tetsuo Ashizawa
Sheng-Han Kuo
Sheng-Han Kuo
spellingShingle Chih-Chun Lin
Chih-Chun Lin
Tetsuo Ashizawa
Sheng-Han Kuo
Sheng-Han Kuo
Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
Frontiers in Neurology
ataxia
cerebellum
network
consortium
spinocerebellar ataxia
author_facet Chih-Chun Lin
Chih-Chun Lin
Tetsuo Ashizawa
Sheng-Han Kuo
Sheng-Han Kuo
author_sort Chih-Chun Lin
title Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
title_short Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
title_full Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
title_fullStr Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
title_full_unstemmed Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
title_sort collaborative efforts for spinocerebellar ataxia research in the united states: crc-sca and readisca
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2020-08-01
description Spinocerebellar ataxias are progressive neurodegenerative disorders primarily affecting the cerebellum. Although the first disease-causing gene was identified nearly 30 years ago, there is no known cure to date, and only a few options exist for symptomatic treatment, with modest effects. The recently developed tools in molecular biology, such as CRISPR/Cas9 and antisense oligonucleotides, can directly act on the disease mechanisms at the genomic or RNA level in disease models. In a nutshell, we are finally just one step away from clinical trials with therapies targeting the underlying genetic cause. However, we still face the challenges for rare neurodegenerative diseases: difficulty in obtaining a large cohort size for sufficient statistical power and the need for biomarkers and clinical outcome assessments (COA) with adequate sensitivity to reflect progression or treatment responses. To overcome these obstacles, ataxia experts form research networks for clinical trial readiness. In this review, we retrace our steps of the collaborative efforts among ataxia researchers in the United States over the years to study and treat these relentless disorders and the future directions of such research networks.
topic ataxia
cerebellum
network
consortium
spinocerebellar ataxia
url https://www.frontiersin.org/article/10.3389/fneur.2020.00902/full
work_keys_str_mv AT chihchunlin collaborativeeffortsforspinocerebellarataxiaresearchintheunitedstatescrcscaandreadisca
AT chihchunlin collaborativeeffortsforspinocerebellarataxiaresearchintheunitedstatescrcscaandreadisca
AT tetsuoashizawa collaborativeeffortsforspinocerebellarataxiaresearchintheunitedstatescrcscaandreadisca
AT shenghankuo collaborativeeffortsforspinocerebellarataxiaresearchintheunitedstatescrcscaandreadisca
AT shenghankuo collaborativeeffortsforspinocerebellarataxiaresearchintheunitedstatescrcscaandreadisca
_version_ 1724487057262247936